Keyong Xiong

GTI-2040, an antisense agent targeting the small subunit component (R2) of human ribonucleotide reductase, shows potent antitumor activity against a variety of tumors.

Yoon Lee, Aikaterini Vassilakos, Ningping Feng et al. · PubMed · 2003 · 92 citations

Medicine, Oncology, Pharmacology +12

Adenovirus-mediated ribonucleotide reductase R1 gene therapy of human colon adenocarcinoma.

Ming‐Yu Cao, Yoon Seong Lee, Ningping Feng et al. · PubMed · 2003 · 36 citations

Medicine, Molecular Biology, Oncology +15

A self-initiating eukaryotic transient gene expression system based on cotransfection of bacteriophage T7 RNA polymerase and DNA vectors containing a T7 autogene

Xiaozhuo Chen, Yunsheng Li, Keyong Xiong et al. · Nucleic Acids Research · 1994 · 31 citations

Life Sciences, Biotechnology, Molecular Biology +14

Cancer Gene Therapy by Direct Tumor Injections of a Nonviral T7 Vector Encoding a Thymidine Kinase Gene

Xiaozhuo Chen, Yunsheng Li, Keyong Xiong et al. · Human Gene Therapy · 1998 · 25 citations

Medicine, Molecular Biology, Oncology +15

GTI-2501, an antisense agent targeting R1, the large subunit of human ribonucleotide reductase, shows potent anti-tumor activity against a variety of tumors

Yoon Lee, Aikaterini Vassilakos, Ningping Feng et al. · International Journal of Oncology · 2006 · 25 citations · Full text

Medicine, Oncology, Pharmacology +13